antithymocyte globulin

Phase 2Small molecule

Sanofi

antithymocyte globulin is one of 18 small molecule programs targeting Myeloid Diseases. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid DiseasesActive, not recruiting

StsCompleted

TransplantActive, not recruiting

Leukemia, Myeloid, Acute(aml)Not yet recruiting

Myeloid DiseasesPhase 1

Active, not recruiting

StsPreclinical

Completed

TransplantPhase 2

Active, not recruiting

Leukemia, Myeloid, Acute(aml)Preclinical

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Transplant

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 2

1 2

Rituxan

Roche

Phase 2

1 3

Prograf

VVeloxis Pharmaceuticals

Phase 2

1 4

Immunoglobulin

Sanofi

Phase 2

1 5

Intravenous Immunoglobulin

UUniversity of Alabama at Birmingham

Phase 2

1 6

antithymocyte globulin

Sanofi

Phase 2

1 7

BIVV020

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Myeloid Diseases

NCT03531736

Q3 2027

Phase 1Active, not recruiting

Hematologic Malignancies

NCT04098393

Q3 2029

PreclinicalNot yet recruiting

Leukemia, Myeloid, Acute(aml)

NCT07762508

Q2 2030

Phase 2Recruiting

Type 1 Diabetes Mellitus

NCT07216391

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome3 trials

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Completed·PPETHEMA Foundation·Phase 4·NCT00488436·25 enrolled

A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00001839·182 enrolled

Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

Unknown status·OOffice of Rare Diseases (ORD)·Phase 2·NCT00466843·54 enrolled

Hematologic Malignancies3 trials

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Completed·FFate Therapeutics·Phase 1·NCT00890500·12 enrolled

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT01621477·34 enrolled

A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04098393·39 enrolled

Transplantation2 trials

Completed·MMassachusetts General Hospital·Phase 2·NCT00133367·32 enrolled

Cord Blood Transplantation for Patients With Cancer

Terminated·UUniversity of Chicago·Phase 2·NCT01359254·1 enrolled

Severe Aplastic Anemia2 trials

Comparing Therapies for the Treatment of Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001626·33 enrolled

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Completed·MM.D. Anderson Cancer Center·N/A·NCT00427336·9 enrolled

Hematopoietic Stem Cell Transplantation2 trials

Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

Unknown status·—·Phase 2·NCT04778618·63 enrolled

Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

Completed·—·Phase 3·NCT05166967·204 enrolled

24 more indications

Type 1 Diabetes2 trials

Islet Transplantation in Type 1 Diabetes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00434811·48 enrolled

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00434850·14 enrolled

Kidney Transplant2 trials

Thymoglobulin Induction in Kidney Transplant Recipients

Unknown status·UUniversity of Oxford·Phase 3·NCT01239563·40 enrolled

Efficacy of Islet After Kidney Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00468117·24 enrolled

Lymphoma1 trial

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Terminated·SStanford University·Phase 2·NCT00481832·50 enrolled

T1D1 trial

STOP-T1D Low-Dose (ATG)

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04291703·2 enrolled

Refractory1 trial

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

Withdrawn· Amgen logo

Amgen·Phase 2·NCT05323617

Islet Transplantation1 trial

B-Lymphocyte Immunotherapy in Islet Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00468442·2 enrolled

Aplastic Anemia1 trial

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Completed·MMedical College of Wisconsin·Phase 2·NCT02918292·32 enrolled

Completed·—·Phase 1·NCT00697684·29 enrolled

Treatment1 trial

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00515099·58 enrolled

CML1 trial

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00499889·42 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00720629·8 enrolled

Myelodysplasia1 trial

Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

Completed·—·Phase 2·NCT00005937·42 enrolled

Stem Cell Transplantation1 trial

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00385788·52 enrolled

Hematologic Malignancy1 trial

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Completed·NNanfang Hospital, Southern Medical University·N/A·NCT02487069·876 enrolled

Bone Marrow Transplantation1 trial

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02702960

Dyskeratosis Congenita1 trial

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00455312·36 enrolled

Kidney1 trial

Regulatory T Cell Modulation in Kidney Transplantation With Biologic Blockade of Dual Effector Pathways, CD28 and IL-6 (CTOT-24)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT04066114·24 enrolled

Type 1 Diabetes Mellitus1 trial

Adaptive Platform Trial to Delay Progression From Stage 2 to Stage 3 Type 1 Diabetes: Comparing Teplizumab With Low-dose Anti-Thymocyte Globulin (ATG) Protocol TN-40A

Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT07216391·60 enrolled

Transplant1 trial

A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05156710·48 enrolled

Leukemia, Myeloid, Acute(AML)1 trial

A Single-Arm, Prospective Clinical Study of the Efficacy and Safety of VABu Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Non-High-Risk AML Patients in CR1 With Low Performance Status (ECOG ≥ 2) or High Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI ≥ 2)

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Preclinical·NCT07762508·42 enrolled

Myeloid Diseases1 trial

Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03531736·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for antithymocyte globulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — antithymocyte globulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for antithymocyte globulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

antithymocyte globulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q3 2029

Q2 2030

Trials by Indication[1]

Myelodysplastic Syndrome3 trials

Hematologic Malignancies3 trials

Transplantation2 trials

Severe Aplastic Anemia2 trials

Hematopoietic Stem Cell Transplantation2 trials

Type 1 Diabetes2 trials

Kidney Transplant2 trials

Lymphoma1 trial

T1D1 trial

Refractory1 trial

Islet Transplantation1 trial

Aplastic Anemia1 trial

Acute Lymphoblastic Leukemia1 trial

Anemia1 trial

Survival1 trial

Stem Cell Transplant1 trial

Treatment1 trial

CML1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Myelodysplasia1 trial

Stem Cell Transplantation1 trial

Hematologic Malignancy1 trial

Bone Marrow Transplantation1 trial

Dyskeratosis Congenita1 trial

Kidney1 trial

Type 1 Diabetes Mellitus1 trial

Transplant1 trial

Leukemia, Myeloid, Acute(AML)1 trial

Myeloid Diseases1 trial

References

Drug Info

Quick Facts

Related News